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Abstract
Prostaglandin induced signalling is involved in different cancers. As previously described, the EP3 receptor expression 
decreases with increasing stage of cervical intraepithelial lesions (CIN). In addition, in cervical cancer EP3 is an independent 
prognosticator for overall survival and correlates with FIGO stages. Currently the role of Prostaglandin 2 receptor 2 (EP2) 
in CIN is unknown. The aim of this study was to analyse the expression of EP2 for potential prognostic value for patients 
with cervical dysplasia. EP2 expression was analysed by immunohistochemistry in 33 patient samples (CIN1–3) using the 
immune-reactivity scoring system (IRS). Expression levels were correlated with clinical outcome to analyse prognostic rel-
evance in patients with CIN2. Data analysis was performed using non parametric Kruskal–Wallis and Spearman rank sum test. 
Cytoplasmic expression levels of EP2 correlated significantly (p < 0.001) with different grades of cervical dysplasia. Median 
EP2-IRS in CIN1 was 2 (n = 8), 3 in CIN2 (n = 9) and 6 in CIN3 (n = 16). Comparing regressive (n = 3, median IRS = 2) 
to progressive (n = 6, median IRS = 4) CIN2 cases the median IRS differed significantly (p = 0.017). Staining intensity 
(p = 0.009) and IRS (p = 0.005) of EP2 and EP3 correlate inversely. EP2 expression level significantly increases with higher 
grade of CIN and could qualify as a potential prognostic marker for the regressive or progressive course in CIN2 lesions. 
These findings emphasize the significant role of PGE2 signalling in CIN and could help to identify targets for future therapies.
Keywords EP-receptor · EP2 · Prostaglandin E2 · CIN · Cervical intraepithelial neoplasia · Cervical cancer HPV
Introduction
After breast-, colorectal- and lung cancer, cervical can-
cer represents the fourth most common malignant tumour 
in women worldwide (Wallis 2014; Watson et al. 2014). 
Approximately 500,000 women worldwide are newly 
diagnosed with cervical cancer per year. 260,000 women 
die from the disease each year (Gottlieb 2016; Jiang et al. 
2015; Landy et al. 2016). Incidence and mortality of cer-
vical cancer correlates negatively with the Human Devel-
opment Index and varies extremely in geographic contexts 
(Wentzensen 2016). Regarding Germany, 4500 women were 
diagnosed with cervical cancer in 2014 and 1500 of these 
patients died tumour associated (Zentrum fur Krebregister-
daten 2019). After the implementation of Pap smear screen-
ing, which detects precursor lesions of cervical epithelium, 
incidence dropped considerably (Hester et al. 2019). The 
persistent infection with specific types of high-risk papil-
lomaviruses is considered the main risk of intraepithelial 
neoplasia and especially in the development of cervical 
cancer (Schiffman et al. 2011). The precursor lesions were 
formerly called cervical intraepithelial neoplasia (CIN) and 
ranged from CIN1 to CIN3 (Santesso et al. 2016). In 2014 
the histological WHO classification has been altered, and 
cervical intraepithelial neoplasia is referred to as squamous 
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intraepithelial lesion (SIL) since 2014 (Lu and Chen 2014). 
The lesions are divided in low grade (LSIL) and high grade 
squamous intraepithelial lesions (HSIL). CIN2 and CIN3 
are now combined in HSIL (Lu and Chen 2014). However, 
pathologists still specify their diagnosis with CIN2/CIN3 
due to the risk of progression to a cervical carcinoma that 
may differ between CIN2 and CIN3 (Luo et al. 2018; Papout-
sis et al. 2017). Consequently, the therapy options also vary 
from conservative approaches to surgical treatments (Saah-
Briffaut et al. 2006). Young women in childbearing age 
could especially profit from a watchful waiting strategy as 
conization increases the appearance of pregnancy compli-
cations such as cervical insufficiency and preterm labour 
(Wilkinson et al. 2015). However, apart from the size of the 
lesion there is no established marker for the prediction of 
progression or remission of CIN2 lesions (Kühn et al. 2015).
Heidegger et al. previously indicated that the prostaglan-
din E2-receptor EP3 is an independent negative prognostic 
factor in cervical cancer patients. The expression levels and 
the clinical outcome were proven to correlate with tumour 
stage (Heidegger et al. 2017). In addition, Hester et al. 
demonstrated that EP3 receptor expression levels correlate 
inversely with grades of CIN (Hester et al. 2019). Our aim 
was to further investigate the role of prostaglandin receptors 
in cervical intraepithelial neoplasia. This study is focussed 
on the EP2 receptor, as it is unique among all EP recep-
tors. The fact that it is not desensitized by Prostaglandin E2 
(PGE2) sets it apart from other EP receptors and highlights 




The cervical tissue samples used in this study were col-
lected from patients treated between 2007 and 2014 in the 
Department of Gynaecology and Obstetrics from Ludwig-
Maximilians-University of Munich, Germany. This cohort 
was analysed in previous studies from our group (Hester 
et al. 2019; Kolben et al. 2016; Vogelsang et al. 2020). Due 
to multiple sections the CIN lesions got lost on the slides 
in many cases, which therefor had been excluded from the 
present study.
In total, 38 tissue samples of cervical dysplasia were 
immunohistochemically stained with anti-EP2-antibody; 
the staining was successful in 33 cases. Of these, 8 were 
classified as CIN1, 9 as CIN2 and 16 as CIN3. On their first 
visit all patients were tested positive for high risk Human 
Papillomavirus (Hybrid Capture 2, Quiagen). Histopatho-
logical grade of dysplasia and diagnosis were confirmed by 
a second gynaecological pathologist. Regarding the CIN2 
collective, only cases with either a histologically confirmed 
progress (n = 6) or regress (n = 3) were used. The follow-up 
interval for patients with CIN2 ranged from 5 to 14 months. 
The cases that were classified as CIN2 at the latest possible 
date and had been ranked as CIN3 previously, were defined 
as regress. CIN2, which had progressed from a former CIN1 
were also defined as progress.
The tissue samples were eligible for this study after 
all routine histopathological diagnostic procedures were 
completed. The data of the patients were completely pseu-
donymized. All analytic procedures complied with the 
Helsinki Declaration guidelines (Reference No. 167-14). 
Informed consent of the patients was guaranteed before 
study participation. The Ethics Committee of the Ludwig-
Maximilians-University (Munich, Germany) accepted the 
design of the study.
Immunohistochemistry
The immunohistochemistry of the paraffin-embedded 
cervical tissue samples was conducted as according to 
our IHC-protocol, which is provided in the supplement. 
First the samples were dewaxed for 20 min in xylol, then 
washed in 100% ethanol. In order to suppress the activity 
of the endogenous peroxidase slides were placed into 3% 
methanol/H2O2 for 20 min. Rehydration in a descend-
ing alcohol series followed. The slides were boiled in 
an airtight pot for 5 min at + 100 °C in a trisodium cit-
rate buffer solution (Merck 244 and Merck 6448) with 
pH = 6 to unmask the antigen from formalin-fixation-
associated protein-agglomeration. Washing in distilled 
water and PBS-buffer followed. The first diluent of the 
Polymer kit (ZytoChem Plus HRP Polymer System, Ber-
lin, Germany) was applied for 5 min. The samples were 
incubated overnight at + 4 °C for 16 h with the anti-EP2-
primary-antibody (anti-PTGER2 antibody polyclonal 
rabbit IgG; ABCAM, Cambridge, UK). After washing in 
PBS-buffer Reagents 2 (Post block) and 3 (horseradish 
peroxidase -Polymer) of the Polymer kit were adminis-
tered. Substrate-staining was performed for two and a half 
minutes with DAB (chromogen substrate kit, Dako, Ham-
burg, Germany). Counterstain by hemalaun colouring and 
dehydrogenation in an ascending alcohol series followed, 
before the slides were mounted with “Eukitt” (Orsatec, 
Bobingen, Germany) (Heidegger et al. 2017). Accord-
ing to information in the human protein atlas sigma and 
placenta tissue were chosen as positive control. To get a 
negative control IHC staining was performed as charac-
terized above, replacing the anti-EP2-primary-antibody 
by a rabbit negative control serum. The immune-reac-
tivity scoring system (IRS, Remmele score) was applied 
to rate immunostaining semi-quantitatively using a Leitz 
(Wetzlar, Germany) microscope type Diaplan. The PL 
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Fluotar objective lens provides a magnification/N.A 
10/0.30. Images were captured with a JVC camera type 
KY-F55B with 440,000 pixel for PAL (JVCKENWOOD 
GmbH, Bad Vilbel, Germany) and the DISKUS acqui-
sition software version 4.60.2017—#223 (Technisches 
Büro Hilgers, Königswinter, Germany). All pictures in 
this paper have got an image bit depth of 8bit in RGB-col-
ourmodell. Figures 1d and 2c have got 150 dpi in height 
and width, all others have got 72 dpi. The IRS multiplies 
the intensity of the staining (0 = no, 1 = weak, 2 = moder-
ate, 3 = strong staining) with the percentage of positive 
cells (0 = no staining, 1 ≤ 10% positive cells, 2 = 11–50% 
positive cells, 3 = 51–80% positive cells, 4 ≥ 81% positive 
cells). At an IRS of 0–1 the staining is negative, from 
2–3 it is mildly positive, 4–8 is moderately positive and 
9–12 strongly positive (Remmele et al. 1986). In order to 
obtain more precise numbers also the percentages were 
multiplied with the intensity. The analysis concerning the 
quantity of EP2-receptor expression in CIN2 was blinded 
for regress vs. progress of the dysplasia. 
Immunohistochemistry regarding the EP3 were derived 
from a previous study performed by our group (Hester 
et al. 2019).
Statistical analysis
For statistical analysis SPSS 25 (PASW Statistic, SPSS Inc., 
IBM, IL, USA) was used. To compare the expression of EP2 
in varying levels of the cervical dysplasia the non-parametric 
Kruskal–Wallis rank-sum test was applied. The correlation 
between levels of EP3 and EP2 was tested with the non-
parametric Spearman rank correlation test. p values ≤ 0.05 
were considered as statistically significant. Figures were 
configured with SPSS 25 and Microsoft Power Point 2016 
(Microsoft, Redmond, WA, USA).
Results
EP2 expression increases with progressing grade 
of cervical dysplasia
We compared the EP-2-IR-scores between the groups of 
CIN1-3 to analyse differences in EP2 expression levels. The 
expression of EP2-receptors in the cytoplasm increased sig-
nificantly in correlation with increasing grade of cervical 
dysplasia as shown in Fig. 1a. This difference was statisti-
cally significant when each grade of dysplasia was compared 
to the next higher one. In CIN1 the median EP2-IRS in the 
Fig. 1  The expression of EP2-receptors in the cytoplasm increased 
significantly with increasing grade of cervical dysplasia, displayed 
by boxplots. The median value is stated above the median-line within 
the boxes (a). The images show representative microphotographs of 
EP2 staining in CIN1 (b IRS 2), CIN2 (c IRS 6) and CIN3 (d IRS 9). 
200× magnification was used for picture b, c and d. Scale bars refer to 
100 µm. Asterisk represents statistically significant differences in the 
staining results of CIN1-3
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cytoplasm was 2, in CIN2 incidents the value was 3 and in 
CIN3 cases the median EP2-IRS was 6 (p < 0.001).
Exemplary staining for all grades of CIN are shown in 
Fig. 1b–d.
Cytoplasmic IRS of EP2 positive cells is higher in CIN 
2 lesions with a progressive course of the dysplasia
To determine if EP2-receptor expression might serve as a 
prognostic factor in regard to a progressive or regressive 
course in cervical dysplasia, we compared EP2 expression 
between CIN2 cases with histologically confirmed regress 
or progress. Although the number of cases was little (n = 3 
for regress, n = 6 for progress) the study revealed statistically 
significant differences between the cytoplasmatic IRS of 
EP2-receptor expressions. In regressive cases the median IR-
score was 2, while it was 4 in progressive cases (p = 0.017) 
as shown in Fig. 2a. Figure 2b and c display the different 
staining in regressive (Fig. 2b) versus progressive (Fig. 2c) 
CIN2 samples (p = 0.017).
Intensity and IR‑Score of EP2 correlates negatively 
with EP3 IRS and intensity
Former research indicated that EP3-receptor expression 
decreases with increasing grade of cervical dysplasia (Hes-
ter et al. 2019). The non-parametric Spearman correlation 
test revealed that both staining intensity and IRS of EP3 and 
EP2 correlate negatively on a significant level as presented 
in Table 1 and Fig. 3a.
Figure 3b and c show the comparison of the staining 
results in the same tissue sample of CIN1 for a staining with 
EP2 (IRS 0) and EP3 (IRS 12), representing the inverse cor-
relation of the receptor types.
Discussion
Herein we analysed the expression of the EP2 receptor 
in CIN samples for potential prognostic information for 
patients with cervical dysplasia. First, the level of EP2 
Fig. 2  The median IR-score in regressive cases and in progressive 
cases differs significantly as shown by the boxplots (a). The differ-
ent staining results with the anti-EP2-antibody in regressive (b IRS 1) 
versus progressive (c IRS 6) CIN2 samples (p = 0.017). 200× magnifi-
cation was used for picture b and c. Scale bars refer to 100 µm. Aster-
isk represents statistically significant differences comparing regres-
sive and progressive CIN2 cases
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receptor expression was compared to the grade of the dys-
plasia. In addition, we correlated the receptor expression to 
the clinical course of CIN2 samples. The analysis revealed 
that the median IR score of EP2 increases significantly 
with increasing grade of dysplasia (CIN1 = 2, CIN2 = 3, 
CIN3 = 6). CIN2 patients with a regressive clinical course 
had significantly lower EP2 levels compared to those with 
a progressive course. Therefore, increasing EP2 expression 
might indicate a progression of CIN towards cervical cancer.
The small number of CIN samples analysed (n = 33) is a 
critical limitation of our study. The study group proved to 
be adequate powered and well-reviewed by previous studies 
of our work group (Hester et al. 2019; Kolben et al. 2016; 
Vogelsang et al. 2020). However, due to several sections of 
the cervical biopsies, cases with missing CIN on the slide 
had to be excluded in the present study. The possibility of 
a colposcopy sampling error in the follow up check might 
represent an additional potential problem. In general, larger 
patient cohorts and further studies are needed to validate 
our findings.
The EP2 receptor is a G-protein coupled receptor with 
seven transmembrane domains bound to a heterotrimeric 
G-protein comprising the stimulatory Gαs and Gβγ subunits 
Table 1  Correlation between EP3 and EP2 staining results
** represent statistically significant differences at (p < 0.001)
Sig. significance, N number of cases, IRS immunoreactive score
EP3 intensity EP3 IRS
Spearman-Rho EP2 intensity
 Correlation coefficient − 0.470** − 0.486**
 Sig. (2-tailed) 0.009 0.006
 N 30 30
EP2 IRS
 Correlation coefficient − 0.465** − 0.501**
 Sig. (2-tailed) 0.010 0.005
 N 30 30
Fig. 3  Correlation diagram 
for IR-score of EP2 and EP3 
representing the inverse correla-
tion of the two prostaglandin 
receptors in CIN tissues (a).
The comparison of the staining 
results in a tissue sample of 
the same patient with CIN1 for 
a staining with the anti-EP2-
antibody (b) and the anti-EP3-
antibody (c) represents this 
inverse correlation. EP2 was not 
detected in the staining (IRS 
0) whereas EP3 was seemingly 
highly expressed (IRS 12). 
200× magnification was used for 
picture b and c. Scale bars refer 
to 100 µm
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(Gilman 1987). It is physiologically activated by PGE2, a 
proinflammatory factor with immunosuppressive function 
(Phipps et al. 1991). PGE2 derives from arachidonic acids, 
which is firstly converted to prostaglandin H2 by cyclooxy-
genase 1/2 (COX 1/2) enzymes and further processed by 
PGE2 synthases (Lambeau and Lazdunski 1999). PGE2 is 
known to operate in many processes such as apoptosis, angi-
ogenesis, chronic inflammation, tumour immunity, prolifera-
tion, migration and invasion (Kalinski 2012). Compared to 
other EP receptors, EP2 is interestingly not desensitized by 
PGE2 and therefore may contribute to deferred phases of 
cellular response (Nishigaki et al. 1996).
The Gα activation of the EP2 receptor can result in 
increased cAMP levels and activation of protein kinase 
A which regulates downstream transcription factors such 
as cAMP response element-binding protein (Fujino et al. 
2005). Direct binding of Gα to regulator of G protein sig-
nalling promotes the release of glycogen synthase kinase-3β 
(GSK-3β) resulting in the activation of β-catenin pathway, 
which triggers the transcription of genes such as c-myc, 
cyclin d1 and vascular endothelial growth factor (Vaid 
et al. 2015). However, activation of serine/threonine-spe-
cific kinase (Akt) via Gβγ and phosphoinositide-3-kinase 
(PI3K) results in the inactivation of GSK-3β (Castellone 
et al. 2005). As a consequence, accumulated β-catenin can 
migrate to the nucleus to stimulate gene transcription via 
TCF/LEF family of transcription factors (Prasad and Kati-
yar 2014). When EP2 forms a complex with β-arrestin it 
can also function in a G protein-independent manner (Chun 
et al. 2009). With β-arrestin as a regulator EP2 can inaugu-
rate pathways of PI3K, Akt, proto-oncogene tyrosine-protein 
kinase Src, extracellular signal-regulated kinases, c-Jun 
N-terminal kinases and epidermal growth factor receptors 
(Sun and Li 2018).
To this point, very little knowledge has been identified of 
the prostaglandin receptors in cervical intraepithelial neo-
plasia. Hester et al. showed that EP3 expression significantly 
decreases with higher grades of cervical intraepithelial neo-
plasia (Hester et al. 2019) and the expression levels of EP3 
correlate with tumour stage as well as clinical outcome as 
Heidegger et al. could confirm (Heidegger et al. 2017). How-
ever, currently comparable studies analysing the expression 
of EP2 in cervical dysplasia are missing.
The role of EP2 has been studied in many malignancies 
as most of the induced pathways play a major role in cell 
proliferation, migration and angiogenesis (Bonanno et al. 
2016; Sobhani et al. 2018). For instance, aberrant expres-
sion of EP2 has been found to be associated with chronic 
inflammation, deregulation of the immune system, angio-
genesis, metastasis as well as multidrug resistance and has 
been observed in cancer of the colon, liver, breast and cer-
vix (Asting et al. 2017; Cui et al. 2017; Gong et al. 2017; 
Huynh 2017). Besides the impact of EP2 activation on cell 
proliferation in cervical squamous intraepithelial lesions the 
immunosuppressive effect of EP2 seems of interest, as only 
HPV infections which are not cleared by the immune system 
can cause SILs and cervical cancer (Westrich et al. 2017).
HPV infections have to evade the host immune defence to 
persist (Schiffman et al. 2011). Incidence of HPV infections 
and HPV associated cancer is increased in patients with nat-
ural killer cell (NK) deficiencies (Orange 2013). Moreover, 
a strong cytotoxic T cell (CTL) response correlates with the 
regression of SILs (Woo et al. 2008). PGE2 contributes to 
an acute local inflammation. However, its prolonged immune 
response can shift cytotoxic T helper cell 1 (Th1), CTL and 
NK cell mediated type 1 immunity towards a Th2, Th17 and 
a regulatory T cell mediated immunity (Walker and Rotondo 
2004). Thereby PGE2 prevents damage of lung or repro-
ductive tissue (Huang et al. 2010; Vancheri et al. 2004). 
Although the limitation of type 1 immunity is pivotal for 
host self-preservation, it contributes to the establishment of 
infections with intracellular organisms and cancer, as they 
both depend on immunosuppression (Kalinski 2012).
den Boon et al. analysed the changes in gene expres-
sion patterns from HPV infected cervical tissue to cervi-
cal cancer. The study displayed that in early lesions, mostly 
genes functioning in DNA replication and cell division were 
upregulated. In transition from CIN3 to cancer the expres-
sion of genes serving the mitochondrial electron chain is 
reduced (den Boon et al. 2015). This suggests a switch from 
oxidative phosphorylation toward anaerobic glycolysis, and 
is known as the “Warburg effect” (Hsu and Sabatini 2008). 
As other DNA viruses, HPV sustain hypoxia inducible factor 
1 alpha (HIF1α), possibly also endorsing the Warburg effect 
(Mazzon et al. 2013; Stover 2009). PGE2 also takes part in 
the induction of HIF1α (Jung et al. 2003).
Grabosch et al. revealed in a systemic review that non-
steroidal anti-inflammatory drugs (NSAIDs) and selective 
COX2 inhibitors (celecoxib, rofecoxib) are not effective in 
the treatment of CIN (Grabosch et al. 2018). Other struc-
tures within the COX downstream signalling pathway like 
EP receptors might serve as alternative drug targets (Ganesh 
et al. 2018). Apart from that, levels of EP receptors such as 
EP2 and EP3 (Hester et al. 2019) might serve as potential 
prognostic biomarkers for patients with CIN2 lesions. In 
particular women in child bearing age, who might suffer 
from pregnancy complications after conization could benefit 
from additional prognostic information (Kühn et al.  2015).
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